DEADLINE FOR PRE-APPLICATION (for access to BSL-4 capacities):
07 MARCH 2023, 23:59 CET
Risk Group 4 (RG4) pathogens usually cause serious human or animal disease and can be readily transmitted from one individual to another, directly or indirectly. Effective treatment and preventive measures are not usually available.
The ISIDORe consortium supports scientists with an interest in these pathogens with high individual and community risk.
Researchers are invited to submit any proposal that:
- Can be advanced by access to at least one of our services,
- Falls under one of the following sections (see SCOPE), and
- Is focused on at least one eligible RG4 pathogen (see below and full ISIDORe PPP list).
Access to In vivo models will only be granted to applicants with projects demonstrating sufficient justification (including in vitro evidence and choice of model) for using animals for scientific purposes.
For access to Regulatory advice services, please select the Section closest to your countermeasure of interest.
Services such as Access to clinical samples and Access to clinical trials are not available for this call.
Please consult our full service offer here.
Your proposal must align with at least one of the Sections below:
Section 1: Surveillance & epidemic management
Section 2: Natural history of infectious diseases / Deciphering & understanding pathogens’ biology, host-pathogen interactions and host responses to infection
Section 3: Diagnostics
Section 4: Therapeutics
Section 5: Vaccines
Section 6: Social sciences & epidemiology
Section 7: Vector biology & vector control
ISIDORe PRIORITY PREPAREDNESS PATHOGENS & LIMITATIONS
Your proposal must focus on at least one of the following pathogens (to see the full list of ISIDORe PPPs, follow this link):
|ISIDORe PPPs||Comments and/or limitations|
|Ebola virus||Section 5 (Vaccines) is open for members of the Zaire ebolavirus species only for projects that propose cross-protective vaccine approaches. Projects focused on vaccines against Zaire ebolavirus only are not eligible. All the other Sections are open for members of the Zaire ebolavirus species. All sections are open for all the other species of the Ebolavirus genus.|
|“New World arenaviruses”||Including but not necessarily limited to the Guanarito, Junin, Lujo, Brazilian, Chapare and Machupo viruses|
SUBMISSION OF PRE-APPLICATION & FULL APPLICATION
To submit your pre application:
- Please make sure that you have read (and comply with) our scientific strategy and eligibility conditions
- Prepare your ORCID number. If you do not have one yet, please go to orcid.org to obtain your own in a few clicks
- Please make sure that your project aligns with ISIDORe PPPs and one of the research sections of interest
- Prepare a brief description of your request (500 characters max)
- Select the service you want to apply for from our catalogue
- Fill out and submit the ISIDORe pre-application form at the bottom of the catalogue page of interest. You will receive a notification with your ISIDORe project number as well as additional guidelines for the preparation of your full application.
For multi-services requests, we’ll be happy to help: please contact us
To submit your full application:
- Follow the guidelines you received along with your ISIDORe project number.
- Your full application must be submitted within 6 weeks upon receipt of your ISIDORe project number.
For proposals requesting access to BSL-4 capacities:
Full applications can be submitted until 07 March 2023, 23.59 CET . Proposals will be evaluated, selected and implemented on a rolling basis. The call may be suspended before the deadline should funding run out.
For proposals requesting access to non BSL-4 capacities:
Proposals will be evaluated, selected and implemented on a rolling basis as long as funding remains.
Direct access to the catalogue pages
- Analytical services
- Cell models
- In vivo models
- Immuno-monitoring & profiling
- Support for diagnostic & therapeutic development
- Support for vaccine development
- Clinical samples
- Regulatory advice, trial preparation & access to clinical trials
- Social sciences & epidemiology